Alzheimer’s and brain health could soon be detected using an eye exam
Soon, an eye examination may be all that is needed to confirm a diagnosis of Alzheimer's disease, according to researchers at Duke's Health.
4 PM production | Shutterstock
Duke Eye Center recently recruited and studied the retinas of over 200 individuals to see if there were any differences between those with Alzheimer's and those without. The results of the study titled, “Retinal Microvascular and Neurodegenerative Changes in Alzheimer’s Disease and Mild Cognitive Impairment Compared with Control Participants,” were published in the latest issue of the journal Ophthalmology Retina.
The results showed that people who have a healthy brain function have a dense microscopic network of blood vessels in the retina, which can be observed through an eye examination. This web-like network of vessels was much less pronounced in patients with Alzheimer's disease.
The data is based on retinal images from 133 healthy participants and 39 individuals with Alzheimer's disease. Age, gender, level of education was adjusted for all cases and controls to remove the influence of bias in the results.
Duke ophthalmologist and retinal surgeon Sharon Fekrat, senior author of the study said that the differences were significant among cases and controls:
The team found that there were tell-tale signs of changes in the retinal blood vessels among those who have a mild cognitive impairment, a known precursor for Alzheimer’s disease. This is due to changes in the retinal nerve layers with mild cognitive impairment and Alzheimer’s.
He said that they used a non-invasive technology called optical coherence tomography angiography (OCTA) to measure the blood flow in each of the layers of the retina. Some of the changes detected were in capillaries or blood vessels that measured less than the width of a human hair he explained.
Fekrat said, “Ultimately, the goal would be to use this technology to detect Alzheimer's early, before symptoms of memory loss are evident, and be able to monitor these changes over time in participants of clinical trials studying new Alzheimer's treatments.”
The research was funded by the National Institutes of Health, 2018 Unrestricted Grant from Research to Prevent Blindness and the Karen L. Wrenn Alzheimer's Disease Award.
No hay comentarios:
Publicar un comentario